Physician profile
Lottie A Walker
NPI 1841362159
$1,298.20
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $189 · 2021: $359 · 2022: $186 · 2023: $43.44 · 2024: $73.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $116.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $231.33 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.41 | 2020-2024 | Trintellix |
| Bausch Health US, LLC | $185.08 | 2019-2022 | |
| Lundbeck LLC | $149.48 | 2019-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $132.15 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $104.59 | 2019-2021 | |
| Allergan, INC. | $93.45 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $40.12 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $36.29 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.33 | 2023-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $28.18 | 2021 | |
| Alkermes, INC. | $17.78 | 2022 | |
| Validus Pharmaceuticals LLC | $16.41 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.95 | 2019 | |
| Adlon Therapeutics L.P. | $15.65 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lottie Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.